Abstract
In all, 17 consecutive patients in hematological complete remission (HCR) of acute promyelocytic leukemia (APL) received allogeneic stem cell transplantation (SCT) from an HLA-identical sibling and were monitored by reverse transcriptase polymerase chain reaction of PML/RARα prior and after transplant. Median age was 31 years (range 3–50 years). At 10 years, the actuarial probabilities of nonrelapse mortality, relapse and disease-free survival were 32% (95% CI: 8–56%), 33% (95% CI: 6–60%) and 46% (95% CI: 22–70%). Six patients tested PCR +ve (1st HCR n=2; 2nd HCR n=3; 3rd HCR n=1) and 11 PCR −ve (2nd HCR n=11) pre-SCT. Of the six patients PCR +ve, two showed early persistence of PCR positivity and converted to sustained PCR negativity after CSA withdrawal (one died of secondary tumor in molecular remission and one is alive in relapse), while four converted to PCR −ve rapidly (one died of the underlying disease and three are in molecular remission). Of the 11 patients PCR −ve pre-SCT, six died (four of transplant-related mortality, one of relapse and one after heart transplantation) and five are alive, four in molecular remission and one is in relapse. Allogeneic SCT seems a valid option for advanced APL, particularly for the poor prognostic group of patients with pre-SCT molecularly persistent disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia
Rare Cancers and Therapy Open Access 21 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukaemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
Estey E, Thall PF, Pierce S, Kantarjian H, Keating M . Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.
Soignet S, Fleischauer A, Polyak T, Heller G, Warrell Jr RP . All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40 (Suppl): S25–S29.
Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiroka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78–85.
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93: 4131–4143.
Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999; 94: 3015–3021.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.
Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362–1370.
Diverio D, Rossi V, Avvisati G, De Santis S, Pestilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukaemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ Trial. Blood 1998; 92: 784–789.
Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.
Nabhan C, Metha J, Tallman MS . The role of bone marrow transplantation in acute promyelocytic leukaemia. Bone Marrow Transplant 2001; 28: 219–226.
Mandelli F, Labopin M, Granena A, Iriondo A, Prentice G, Bacigalupo A et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group of Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1994; 14: 293–298.
Glucksberg H, Storb R, Fefer A . Clinical manifestations of graft-versus-host-disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL, Sale GE, Hackman R, Tsoi MS, Storb R et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Chomczynsky P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate–phenol chloroform extraction. Ann Biochem 1987; 162: 156–159.
Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F et al. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214–1216.
Sanz M, Arcese W, De La Rubia J, Lo Coco F, Labopin M, Bacigalupo A et al. Stem cell transplantation (SCT) for acute promyelocytic leukaemia in the ATRA era: a survery of the European Blood and Marrow Transplantation Group (EBMT). Blood19 Refs. cited in the ref. list, but only 18 cited in text, pl. check. 2000; 96(Suppl. 1): 522a (Abstract 2247).
Acknowledgements
This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro), AIL (Associazione Italiana contro le Leucemie), MIUR (Ministero della Università e della Ricerca Scientifica e Tecnologica), CNR (Consiglio Nazionale delle Ricerche) and Ministero della Salute.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lo-Coco, F., Romano, A., Mengarelli, A. et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 17, 1930–1933 (2003). https://doi.org/10.1038/sj.leu.2403078
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403078
Keywords
This article is cited by
-
Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia
Rare Cancers and Therapy (2015)
-
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia
Leukemia (2012)
-
Current treatment strategy of acute promyelocytic leukemia
Frontiers of Medicine (2011)
-
Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML
Bone Marrow Transplantation (2008)
-
Traitement des leucémies aiguës promyélocytaires de l’adulte
Oncologie (2008)